Concepedia

William P. Tong

WP

Statistics

Publications

94

Citations

8.2K

H-Index

45

Active since

1975

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Cornell University

Albany Medical Center Hospital

The University of Texas MD Anderson Cancer Center

Columbia University

William P. Tong is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pharmacology, and oncology.

Top concepts

Publications per year

1975–2018

94

Publications

94

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

William Kevin Kelly, Owen A. O’Connor, Lee M. Krug et al. · Journal of Clinical Oncology · 2005 · 898 citations · Full text

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman et al. · Journal of Clinical Oncology · 2002 · 684 citations

, , +15

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Wm. Kevin Kelly, Victoria M. Richon, Owen A. O’Connor et al. · PubMed · 2003 · 623 citations

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

David B. Solit, Fuzhong F. Zheng, Marija Drobnjak et al. · PubMed · 2002 · 435 citations

Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.

John T. Pinto, Brian Suffoletto, Tyler M. Berzin et al. · PubMed · 1996 · 390 citations

, , +15

1–5 of 94